Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients

Next Previous
Trial Profile

A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel
  • Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms TCHL-Phase-II

Most Recent Events

  • 01 Jun 2021 Results performing tumour-associated lymphocytes analysis and T-cell analysis by immunohistochemistry on the pretreatment and on-treatment samples from NCT01485926, published in the Breast Cancer Research and Treatment
  • 29 Oct 2020 Results published in the Clinical Cancer Research
  • 24 Jun 2020 Results assessing effects of neo-adjuvant chemotherapy on the phenotype and cytotoxic capacity of peripheral blood mononuclear cells breast cancer patients presented at the 111th Annual Meeting of the American Association for Cancer Research - II

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top